As DNA damage-induced ERK activation inhibited DDR-associated apoptosis in myeloma and leukemia [16, 17], inhibition of ERK activation will be expected to enhance the efficacy of genotoxic drugs on these cancers. The gene discussed is MAPK1; the disease is plasma cell myeloma.